While further studies utilizing advanced and physiologically relevant in vivo models that replicate certain types of cancer are necessary, the current evidence suggests that MALAT1 may hold promise as a primary candidate for future clinically applicable lncRNA-based therapies against MI. This evidence concerns the gene MALAT1 and cancer.